NYSE accepts American Strategic Investment’s compliance plan 

NESR signs unconventional frac contract at Saudi-US Investment Forum 

Simply Wall St 3 min read In late November 2025, Zoetis Inc. announced that the European Commission granted marketing authorization for Lenivia® (izenive™), a new monoclonal antibody therapy providing up to three months of osteoarthritis pain relief in dogs after a single injection. This marks a significant expansion of Zoetis’s companion animal pain management portfolio,...